Promedior Appoints Elizabeth Trehu, M.D., as Chief Medical Officer  
10/15/2012 9:50:26 AM

MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced the appointment of Elizabeth G. Trehu, M.D., as Chief Medical Officer (CMO). As CMO, Dr. Trehu will oversee all clinical development and regulatory activities for the company, as Promedior rapidly advances its product candidates in human clinical trials for diseases involving fibrosis, including idiopathic pulmonary fibrosis (IPF), myelofibrosis and retinal diseases. Dr. Trehu is a seasoned biopharmaceutical executive with experience moving early stage R&D programs successfully through clinical development and product commercialization. She will report directly to Promedior’s CEO Suzanne Bruhn, Ph.D., and will serve as a member of the company’s executive management team.